A Case of Fulminant Fusobacterium necrophorum Bacteremia Secondary to Non-severe COVID-19
暂无分享,去创建一个
[1] C. Steves,et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study , 2022, The Lancet.
[2] N. Huy,et al. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? , 2021, The Lancet Respiratory Medicine.
[3] Chih-Cheng Lai,et al. COVID-19 associated with pulmonary aspergillosis: A literature review , 2020, Journal of Microbiology, Immunology and Infection.
[4] A. Almohaya,et al. Fusobacterium bloodstream infections: A literature review and hospital-based case series. , 2020, Anaerobe.
[5] K. Laupland,et al. Incidence, risk factors, and outcomes of Fusobacterium species bacteremia , 2013, BMC Infectious Diseases.
[6] C. Karkos,et al. Lemierre's syndrome: A systematic review , 2009, The Laryngoscope.
[7] Yasuhiro Ohtomo,et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria* , 2006, Critical care medicine.
[8] S. Kehl,et al. Increased diagnosis of Lemierre syndrome and other Fusobacterium necrophorum infections at a Children's Hospital. , 2003, Pediatrics.